TINA NASRIN

ONISILOS MSCA COFUND FELLOW

Πανεπιστήμιο Κύπρου
University of Cyprus

ONISILOS

MSCA COFUND 2020

At the University of Cyprus, she is focusing her research on the synthesis of silver nanoparticles from bacteria and on gut microbiota modulation with the silver nano-rods in a microfluidic model of the gut. This project is collaborative, under the mentorship of Dr. Chrysafis Andreou, Assistant Professor, Department of Electrical and Computer Engineering, and Dr. Yiorgos Apidianakis, Associate Professor of Genetics, Department of Biological Sciences.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No 101034403

Dr. Tina Nasrin, an ONISILOS MSCA COFUND fellow, has a master's degree in Biotechnology and a Ph.D. in Biochemistry from Kalyani University, India. Her Ph.D. work conferred the biosynthesis of nanoparticles that have antimicrobial and anticancer activities. She is trained in the methodology of nanoparticle synthesis at the Centre for the Development of Nanoscience and Nanotechnology, CEDENNA, Santiago, Chile. Additionally, she was a teacher at an academic institute in India.

At the University of Cyprus, under the ONISILOS project, she is focusing her research on the synthesis of silver nanoparticles from bacteria and on gut microbiota modulation with the silver nano-rods in a microfluidic model of the gut. This project is collaborative, under the mentorship of Dr. Chrysafis Andreou, Assistant Professor, Department of Electrical and Computer Engineering, and Dr. Yiorgos Apidianakis, Associate Professor of Genetics, Department of Biological Sciences. Biosynthesized silver nanorods may be useful as a targeted antibacterial agent against gut bacteria known to promote colorectal cancer. Hereby this approach has a prospective future for preventing the disease, but also prolonging the survival rates and improving the quality of life of patients with colorectal cancer. Optimistically the outcome of this project could lead to a more effective and patient-friendly strategy to overcome the complications of existing therapies.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No 101034403